Compare Cytokinetics Inc (CYTK) vs Garmin Ltd. (GRMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Garmin Ltd. — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Garmin Ltd. trades at $268.36 (market cap $51.77B). The key difference: Garmin Ltd. is far larger — about 6× Cytokinetics Inc's market cap, and Garmin Ltd. pays a 1.56% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Garmin Ltd. for 83 Days on average.
| CYTK | GRMN | |
|---|---|---|
Market Cap | $8.62B | $51.77B |
Volume | 2,594,626 | 961,398 |
Sector | Health | Technology |
52-Week High | $87.26 | $313.16 |
52-Week Low | $54.76 | $187.10 |
Typical Hold Time | 19 Days | 83 Days |
Enterprise Value | $8.72B | $49.28B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
Garmin (GRMN) trades at $268.44, down 2.8% on the day, amid a bearish technical signal. The stock has demonstrated strong fundamental performance with revenue growing from $4.9B in 2022 to $7.25B in 2025 and net income reaching $1.66B. Recent earnings beats and consistent dividend payments highlight operational strength, while analyst consensus targets $320.25, suggesting potential upside from current levels.
The outlook remains positive given robust profitability and product innovation, but risks include competitive pressures and market volatility. Institutional ownership trends and a Zacks Strong Buy upgrade reflect confidence, yet the stock faces headwinds from broader economic conditions and execution challenges in maintaining growth momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
